Premiere Eye Referral Center and Optical (PERC) has unveiled its groundbreaking services in ophthalmic care - LASIK & ...

Andrew G. Lee, MD, and Drew Carey, MD, highlight how chronic lymphocytic leukemia can mimic Graves’ orbitopathy, underscoring ...

Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on developing innovations for ophthalmic and neuro-ophthalmic diseases with significant unmet medical ...

Oculis Holding ( (OCS) ) has shared an announcement. On October 6, 2025, Oculis Holding AG announced the advancement of its drug candidate Privosegtor into a registrational program for ...

Privosegtor (also known as OCS-05) is a “first-in-class peptoid small molecule” for neuroprotective therapy for acute optic ...

Successful meeting with FDA enables advancement into pivotal development with Privosegtor in Acute Optic Neuritis (AON) and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Oculis will launch ...

“More millennials are now presenting with problems from too much screen time. We’re seeing a significant increase in dry eyes ...

ZUG, Switzerland, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations for ophthalmic and ...

Privosegtor ACUITY Trial showed Improved LCVA and preservation of Ganglion Cells in Acute Optic Neuritis. Results from a Multicenter Randomized Placebo-Controlled Double-Masked Trial ZUG, Switzerland, ...

Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis to be presented in EURETINA late-breaking session Expanded data analysis from Phase 3 Stage 1 DIAMOND program for OCS-01 ...

Aim To conduct an analysis of ophthalmic manifestations in leukaemic patients and evaluate their impact on visual outcomes and disease remission. Methods This retrospective, comparative study included ...